These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36265718)

  • 21. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Roys A; Chang X; Liu Y; Xu X; Wu Y; Zuo D
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):679-688. PubMed ID: 31256210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
    Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
    Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
    Huang Z; Zhang Y; Xu Q; Song L; Li Y; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zeng L; Zhang Y
    Lung Cancer; 2024 Jun; 192():107827. PubMed ID: 38795459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
    Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
    Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH; Mok K; Leung LK; Mok TS
    Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
    Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
    J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ROS1-rearranged NSCLC With Secondary Resistance Mutation: Case Report and Current Perspectives.
    Guisier F; Piton N; Salaun M; Thiberville L
    Clin Lung Cancer; 2019 Nov; 20(6):e593-e596. PubMed ID: 31395437
    [No Abstract]   [Full Text] [Related]  

  • 28. Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion.
    Ren S; Huang S; Ye X; Feng L; Lu Y; Zhou C; Zhao J; He T; Wang J; Li B
    Cancer Treat Res Commun; 2021; 27():100377. PubMed ID: 33945921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
    PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
    Xu CW; Wang WX; Huang RF; He C; Liao XH; Zhu YC; Du KQ; Zhuang W; Chen YP; Chen G; Fang MY
    Thorac Cancer; 2017 Nov; 8(6):714-719. PubMed ID: 28845578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
    Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
    J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crizotinib inhibition of
    Bebb DG; Agulnik J; Albadine R; Banerji S; Bigras G; Butts C; Couture C; Cutz JC; Desmeules P; Ionescu DN; Leighl NB; Melosky B; Morzycki W; Rashid-Kolvear F; Lab C; Sekhon HS; Smith AC; Stockley TL; Torlakovic E; Xu Z; Tsao MS
    Curr Oncol; 2019 Aug; 26(4):e551-e557. PubMed ID: 31548824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired resistance to crizotinib from a mutation in CD74-ROS1.
    Awad MM; Katayama R; McTigue M; Liu W; Deng YL; Brooun A; Friboulet L; Huang D; Falk MD; Timofeevski S; Wilner KD; Lockerman EL; Khan TM; Mahmood S; Gainor JF; Digumarthy SR; Stone JR; Mino-Kenudson M; Christensen JG; Iafrate AJ; Engelman JA; Shaw AT
    N Engl J Med; 2013 Jun; 368(25):2395-401. PubMed ID: 23724914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
    Katayama R; Gong B; Togashi N; Miyamoto M; Kiga M; Iwasaki S; Kamai Y; Tominaga Y; Takeda Y; Kagoshima Y; Shimizu Y; Seto Y; Oh-Hara T; Koike S; Nakao N; Hanzawa H; Watanabe K; Yoda S; Yanagitani N; Hata AN; Shaw AT; Nishio M; Fujita N; Isoyama T
    Nat Commun; 2019 Aug; 10(1):3604. PubMed ID: 31399568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
    Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
    J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
    Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
    Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrinsic resistance to ROS1 inhibition in a patient with CD74-ROS1 mediated by AXL overexpression.
    Peters TL; Chen N; Tyler LC; Le AT; Dimou A; Doebele RC
    Thorac Cancer; 2023 Nov; 14(33):3259-3265. PubMed ID: 37727007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
    Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
    BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.